schliessen

Filtern

 

Bibliotheken

Cover Image

Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib

Context: Sorafenib, a tyrosine kinase inhibitor, is a common first-line therapy for advanced differentiated thyroid cancer (DTC). However, responses are not durable and drug toxicity remains a problem. Objective: The objective of the study was to determine the efficacy of salvage therapy after first... Full description

Journal Title: The journal of clinical endocrinology and metabolism 2014-06, Vol.99 (6), p.2086-2094
Main Author: Dadu, Ramona
Other Authors: Devine, Catherine , Hernandez, Mike , Waguespack, Steven G , Busaidy, Naifa L , Hu, Mimi I , Jimenez, Camilo , Habra, Mouhammad A , Sellin, Rena V , Ying, Anita K , Cote, Gilbert J , Sherman, Steven I , Cabanillas, Maria E
Format: Electronic Article Electronic Article
Language: English
Subjects:
Abridged Index Medicus
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Papillary, Follicular - drug therapy
Carcinoma, Papillary, Follicular - mortality
Carcinoma, Papillary, Follicular - pathology
Chemotherapy, Adjuvant
Drug Resistance, Neoplasm - drug effects
Endocrine Care
Female
Humans
Male
Middle Aged
Molecular Targeted Therapy
Neoadjuvant Therapy
Neoplasm Metastasis
Niacinamide - analogs & derivatives
Niacinamide - therapeutic use
Phenylurea Compounds - therapeutic use
Protein Kinase Inhibitors - therapeutic use
Retrospective Studies
Salvage Therapy - methods
Thyroid Neoplasms - drug therapy
Thyroid Neoplasms - mortality
Thyroid Neoplasms - pathology
Treatment Failure
Publisher: United States: Endocrine Society
ID: ISSN: 0021-972X
Link: https://www.ncbi.nlm.nih.gov/pubmed/24628550
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4037722
title: Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib
format: Article
creator:
  • Dadu, Ramona
  • Devine, Catherine
  • Hernandez, Mike
  • Waguespack, Steven G
  • Busaidy, Naifa L
  • Hu, Mimi I
  • Jimenez, Camilo
  • Habra, Mouhammad A
  • Sellin, Rena V
  • Ying, Anita K
  • Cote, Gilbert J
  • Sherman, Steven I
  • Cabanillas, Maria E
subjects:
  • Abridged Index Medicus
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols - therapeutic use
  • Carcinoma, Papillary, Follicular - drug therapy
  • Carcinoma, Papillary, Follicular - mortality
  • Carcinoma, Papillary, Follicular - pathology
  • Chemotherapy, Adjuvant
  • Drug Resistance, Neoplasm - drug effects
  • Endocrine Care
  • Female
  • Humans
  • Male
  • Middle Aged
  • Molecular Targeted Therapy
  • Neoadjuvant Therapy
  • Neoplasm Metastasis
  • Niacinamide - analogs & derivatives
  • Niacinamide - therapeutic use
  • Phenylurea Compounds - therapeutic use
  • Protein Kinase Inhibitors - therapeutic use
  • Retrospective Studies
  • Salvage Therapy - methods
  • Thyroid Neoplasms - drug therapy
  • Thyroid Neoplasms - mortality
  • Thyroid Neoplasms - pathology
  • Treatment Failure
ispartof: The journal of clinical endocrinology and metabolism, 2014-06, Vol.99 (6), p.2086-2094
description: Context: Sorafenib, a tyrosine kinase inhibitor, is a common first-line therapy for advanced differentiated thyroid cancer (DTC). However, responses are not durable and drug toxicity remains a problem. Objective: The objective of the study was to determine the efficacy of salvage therapy after first-line sorafenib failure. Design: This was a retrospective review at M. D. Anderson Cancer Center from January 2005 to May 2013. Patients: The study included patients with metastatic DTC who received salvage therapy after their initial sorafenib failure (group 2). Patients who received first-line sorafenib only (group 1) were evaluated for comparison of overall survival (OS). Outcome Measures: Progression-free survival, best response, and median OS were measured. Results: Sixty-four patients with metastatic, radioactive iodine refractory DTC were included; 35 were in group 1 and 25 were in group 2, and the groups were well balanced. Median OS of all 64 patients receiving first line sorafenib was 37 months; median OS was significantly longer with salvage therapy compared with sorafenib alone (58 vs 28 months, P = .013). In group 2, 17 patients were evaluable for best response, although two patients had toxicity with sorafenib, which was discontinued before restaging. Best responses with first-line sorafenib were partial response in 2 of 15 (13%), stable disease in 10 of 15 (67%), and progressive disease in 3 of 15 (20%) patients. With salvage therapy, partial responses were seen in 7 of 17 (41%) and stable disease in 10 of 17 (59%) patients. Median progression-free survival was 7.4 months with first-line sorafenib and 11.4 months with salvage therapy. Salvage therapy included sunitinib (n = 4), pazopanib (n = 3), cabozantinib (n = 4), lenvatinib (n = 3), and vemurafenib (n = 3). Conclusions: Other targeted agents are effective salvage treatments after sorafenib failure, despite similar mechanisms of action, and should be offered to patients who are able to receive salvage therapy.
language: eng
source:
identifier: ISSN: 0021-972X
fulltext: no_fulltext
issn:
  • 0021-972X
  • 1945-7197
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.638111
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_pubme
recordidTN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4037722
sourceformatXML
sourcesystemPC
sourcerecordid1532949246
originalsourceidFETCH-LOGICAL-15481-afad3b357035c1abd4b7630583052cc188540168844c231bf7eb2645ea682e4d0
addsrcrecordideNp1kt2LEzEUxQdR3Lr65rPk0QdnzedM5kWQal2hoLgVfQt3Mnfa1HRSk-ku_e9NmXVxRQMhhHvOuUl-KYrnjF4wzujrrb3glIlSKK0fFDPWSFXWrKkfFjNKOSubmn8_K56ktKWUSanE4-KMy4prpeis2H4JHknoyRX4a1gjWUFc44gdWW0wwv5I3EDeub7HiMPoYKocY3AdmcNgMZLPMLpcS-TbJpAFOJ8lCxfTWC7dgOQqROhxcO3T4lEPPuGz2_W8-Lp4v5pflstPHz7O3y5LpqRmJfTQiVaomgplGbSdbOtKUKXz5NYyrZWkrNJaSssFa_saW15JhVBpjrKj58WbKXd_aHfY2Xy2CN7so9tBPJoAztyvDG5j1uHaSCrqmvMccDkFhD0O4CLe83YDjiZ0hle1oYgSRdvn57Gy0VZZBOiVZEp0UFVNjnp5e5YYfh4wjWbnkkXvYcBwSCYLeSObzCNLX01SG0NKEfu7royaE2mzteZE2pxIZ_mLP295J_6NNgv4X3nWjRlVOF3a-f-lysl0E_yIMf3whxuMZoPgx42heciq1mU2SFrlXUlPfyzbxGTDoQs2Zuz7iCmZbTjEIbP-d7Nf6xrVVw
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1532949246
display
typearticle
titleRole of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib
creatorDadu, Ramona ; Devine, Catherine ; Hernandez, Mike ; Waguespack, Steven G ; Busaidy, Naifa L ; Hu, Mimi I ; Jimenez, Camilo ; Habra, Mouhammad A ; Sellin, Rena V ; Ying, Anita K ; Cote, Gilbert J ; Sherman, Steven I ; Cabanillas, Maria E
creatorcontribDadu, Ramona ; Devine, Catherine ; Hernandez, Mike ; Waguespack, Steven G ; Busaidy, Naifa L ; Hu, Mimi I ; Jimenez, Camilo ; Habra, Mouhammad A ; Sellin, Rena V ; Ying, Anita K ; Cote, Gilbert J ; Sherman, Steven I ; Cabanillas, Maria E
descriptionContext: Sorafenib, a tyrosine kinase inhibitor, is a common first-line therapy for advanced differentiated thyroid cancer (DTC). However, responses are not durable and drug toxicity remains a problem. Objective: The objective of the study was to determine the efficacy of salvage therapy after first-line sorafenib failure. Design: This was a retrospective review at M. D. Anderson Cancer Center from January 2005 to May 2013. Patients: The study included patients with metastatic DTC who received salvage therapy after their initial sorafenib failure (group 2). Patients who received first-line sorafenib only (group 1) were evaluated for comparison of overall survival (OS). Outcome Measures: Progression-free survival, best response, and median OS were measured. Results: Sixty-four patients with metastatic, radioactive iodine refractory DTC were included; 35 were in group 1 and 25 were in group 2, and the groups were well balanced. Median OS of all 64 patients receiving first line sorafenib was 37 months; median OS was significantly longer with salvage therapy compared with sorafenib alone (58 vs 28 months, P = .013). In group 2, 17 patients were evaluable for best response, although two patients had toxicity with sorafenib, which was discontinued before restaging. Best responses with first-line sorafenib were partial response in 2 of 15 (13%), stable disease in 10 of 15 (67%), and progressive disease in 3 of 15 (20%) patients. With salvage therapy, partial responses were seen in 7 of 17 (41%) and stable disease in 10 of 17 (59%) patients. Median progression-free survival was 7.4 months with first-line sorafenib and 11.4 months with salvage therapy. Salvage therapy included sunitinib (n = 4), pazopanib (n = 3), cabozantinib (n = 4), lenvatinib (n = 3), and vemurafenib (n = 3). Conclusions: Other targeted agents are effective salvage treatments after sorafenib failure, despite similar mechanisms of action, and should be offered to patients who are able to receive salvage therapy.
identifier
0ISSN: 0021-972X
1EISSN: 1945-7197
2DOI: 10.1210/jc.2013-3588
3PMID: 24628550
languageeng
publisherUnited States: Endocrine Society
subjectAbridged Index Medicus ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carcinoma, Papillary, Follicular - drug therapy ; Carcinoma, Papillary, Follicular - mortality ; Carcinoma, Papillary, Follicular - pathology ; Chemotherapy, Adjuvant ; Drug Resistance, Neoplasm - drug effects ; Endocrine Care ; Female ; Humans ; Male ; Middle Aged ; Molecular Targeted Therapy ; Neoadjuvant Therapy ; Neoplasm Metastasis ; Niacinamide - analogs & derivatives ; Niacinamide - therapeutic use ; Phenylurea Compounds - therapeutic use ; Protein Kinase Inhibitors - therapeutic use ; Retrospective Studies ; Salvage Therapy - methods ; Thyroid Neoplasms - drug therapy ; Thyroid Neoplasms - mortality ; Thyroid Neoplasms - pathology ; Treatment Failure
ispartofThe journal of clinical endocrinology and metabolism, 2014-06, Vol.99 (6), p.2086-2094
rights
0Copyright © 2014 by the Endocrine Society
1Copyright © 2014 by The Endocrine Society
2Copyright © 2014 by the Endocrine Society 2014
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-15481-afad3b357035c1abd4b7630583052cc188540168844c231bf7eb2645ea682e4d0
citesFETCH-LOGICAL-15481-afad3b357035c1abd4b7630583052cc188540168844c231bf7eb2645ea682e4d0
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24628550$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Dadu, Ramona
1Devine, Catherine
2Hernandez, Mike
3Waguespack, Steven G
4Busaidy, Naifa L
5Hu, Mimi I
6Jimenez, Camilo
7Habra, Mouhammad A
8Sellin, Rena V
9Ying, Anita K
10Cote, Gilbert J
11Sherman, Steven I
12Cabanillas, Maria E
title
0Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib
1The journal of clinical endocrinology and metabolism
addtitleJ Clin Endocrinol Metab
descriptionContext: Sorafenib, a tyrosine kinase inhibitor, is a common first-line therapy for advanced differentiated thyroid cancer (DTC). However, responses are not durable and drug toxicity remains a problem. Objective: The objective of the study was to determine the efficacy of salvage therapy after first-line sorafenib failure. Design: This was a retrospective review at M. D. Anderson Cancer Center from January 2005 to May 2013. Patients: The study included patients with metastatic DTC who received salvage therapy after their initial sorafenib failure (group 2). Patients who received first-line sorafenib only (group 1) were evaluated for comparison of overall survival (OS). Outcome Measures: Progression-free survival, best response, and median OS were measured. Results: Sixty-four patients with metastatic, radioactive iodine refractory DTC were included; 35 were in group 1 and 25 were in group 2, and the groups were well balanced. Median OS of all 64 patients receiving first line sorafenib was 37 months; median OS was significantly longer with salvage therapy compared with sorafenib alone (58 vs 28 months, P = .013). In group 2, 17 patients were evaluable for best response, although two patients had toxicity with sorafenib, which was discontinued before restaging. Best responses with first-line sorafenib were partial response in 2 of 15 (13%), stable disease in 10 of 15 (67%), and progressive disease in 3 of 15 (20%) patients. With salvage therapy, partial responses were seen in 7 of 17 (41%) and stable disease in 10 of 17 (59%) patients. Median progression-free survival was 7.4 months with first-line sorafenib and 11.4 months with salvage therapy. Salvage therapy included sunitinib (n = 4), pazopanib (n = 3), cabozantinib (n = 4), lenvatinib (n = 3), and vemurafenib (n = 3). Conclusions: Other targeted agents are effective salvage treatments after sorafenib failure, despite similar mechanisms of action, and should be offered to patients who are able to receive salvage therapy.
subject
0Abridged Index Medicus
1Adult
2Aged
3Antineoplastic Combined Chemotherapy Protocols - therapeutic use
4Carcinoma, Papillary, Follicular - drug therapy
5Carcinoma, Papillary, Follicular - mortality
6Carcinoma, Papillary, Follicular - pathology
7Chemotherapy, Adjuvant
8Drug Resistance, Neoplasm - drug effects
9Endocrine Care
10Female
11Humans
12Male
13Middle Aged
14Molecular Targeted Therapy
15Neoadjuvant Therapy
16Neoplasm Metastasis
17Niacinamide - analogs & derivatives
18Niacinamide - therapeutic use
19Phenylurea Compounds - therapeutic use
20Protein Kinase Inhibitors - therapeutic use
21Retrospective Studies
22Salvage Therapy - methods
23Thyroid Neoplasms - drug therapy
24Thyroid Neoplasms - mortality
25Thyroid Neoplasms - pathology
26Treatment Failure
issn
00021-972X
11945-7197
fulltextfalse
rsrctypearticle
creationdate2014
recordtypearticle
recordideNp1kt2LEzEUxQdR3Lr65rPk0QdnzedM5kWQal2hoLgVfQt3Mnfa1HRSk-ku_e9NmXVxRQMhhHvOuUl-KYrnjF4wzujrrb3glIlSKK0fFDPWSFXWrKkfFjNKOSubmn8_K56ktKWUSanE4-KMy4prpeis2H4JHknoyRX4a1gjWUFc44gdWW0wwv5I3EDeub7HiMPoYKocY3AdmcNgMZLPMLpcS-TbJpAFOJ8lCxfTWC7dgOQqROhxcO3T4lEPPuGz2_W8-Lp4v5pflstPHz7O3y5LpqRmJfTQiVaomgplGbSdbOtKUKXz5NYyrZWkrNJaSssFa_saW15JhVBpjrKj58WbKXd_aHfY2Xy2CN7so9tBPJoAztyvDG5j1uHaSCrqmvMccDkFhD0O4CLe83YDjiZ0hle1oYgSRdvn57Gy0VZZBOiVZEp0UFVNjnp5e5YYfh4wjWbnkkXvYcBwSCYLeSObzCNLX01SG0NKEfu7royaE2mzteZE2pxIZ_mLP295J_6NNgv4X3nWjRlVOF3a-f-lysl0E_yIMf3whxuMZoPgx42heciq1mU2SFrlXUlPfyzbxGTDoQs2Zuz7iCmZbTjEIbP-d7Nf6xrVVw
startdate201406
enddate201406
creator
0Dadu, Ramona
1Devine, Catherine
2Hernandez, Mike
3Waguespack, Steven G
4Busaidy, Naifa L
5Hu, Mimi I
6Jimenez, Camilo
7Habra, Mouhammad A
8Sellin, Rena V
9Ying, Anita K
10Cote, Gilbert J
11Sherman, Steven I
12Cabanillas, Maria E
general
0Endocrine Society
1Copyright by The Endocrine Society
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
87X8
9BOBZL
10CLFQK
115PM
sort
creationdate201406
titleRole of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib
authorDadu, Ramona ; Devine, Catherine ; Hernandez, Mike ; Waguespack, Steven G ; Busaidy, Naifa L ; Hu, Mimi I ; Jimenez, Camilo ; Habra, Mouhammad A ; Sellin, Rena V ; Ying, Anita K ; Cote, Gilbert J ; Sherman, Steven I ; Cabanillas, Maria E
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-15481-afad3b357035c1abd4b7630583052cc188540168844c231bf7eb2645ea682e4d0
rsrctypearticles
prefilterarticles
languageeng
creationdate2014
topic
0Abridged Index Medicus
1Adult
2Aged
3Antineoplastic Combined Chemotherapy Protocols - therapeutic use
4Carcinoma, Papillary, Follicular - drug therapy
5Carcinoma, Papillary, Follicular - mortality
6Carcinoma, Papillary, Follicular - pathology
7Chemotherapy, Adjuvant
8Drug Resistance, Neoplasm - drug effects
9Endocrine Care
10Female
11Humans
12Male
13Middle Aged
14Molecular Targeted Therapy
15Neoadjuvant Therapy
16Neoplasm Metastasis
17Niacinamide - analogs & derivatives
18Niacinamide - therapeutic use
19Phenylurea Compounds - therapeutic use
20Protein Kinase Inhibitors - therapeutic use
21Retrospective Studies
22Salvage Therapy - methods
23Thyroid Neoplasms - drug therapy
24Thyroid Neoplasms - mortality
25Thyroid Neoplasms - pathology
26Treatment Failure
toplevelpeer_reviewed
creatorcontrib
0Dadu, Ramona
1Devine, Catherine
2Hernandez, Mike
3Waguespack, Steven G
4Busaidy, Naifa L
5Hu, Mimi I
6Jimenez, Camilo
7Habra, Mouhammad A
8Sellin, Rena V
9Ying, Anita K
10Cote, Gilbert J
11Sherman, Steven I
12Cabanillas, Maria E
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7MEDLINE - Academic
8OpenAIRE (Open Access)
9OpenAIRE
10PubMed Central (Full Participant titles)
jtitleThe journal of clinical endocrinology and metabolism
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Dadu, Ramona
1Devine, Catherine
2Hernandez, Mike
3Waguespack, Steven G
4Busaidy, Naifa L
5Hu, Mimi I
6Jimenez, Camilo
7Habra, Mouhammad A
8Sellin, Rena V
9Ying, Anita K
10Cote, Gilbert J
11Sherman, Steven I
12Cabanillas, Maria E
formatjournal
genrearticle
ristypeJOUR
atitleRole of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib
jtitleThe journal of clinical endocrinology and metabolism
addtitleJ Clin Endocrinol Metab
date2014-06
risdate2014
volume99
issue6
spage2086
epage2094
pages2086-2094
issn0021-972X
eissn1945-7197
notesThis work was supported by the National Institutes of Health/National Cancer Institute under Award P30CA016672.
abstractContext: Sorafenib, a tyrosine kinase inhibitor, is a common first-line therapy for advanced differentiated thyroid cancer (DTC). However, responses are not durable and drug toxicity remains a problem. Objective: The objective of the study was to determine the efficacy of salvage therapy after first-line sorafenib failure. Design: This was a retrospective review at M. D. Anderson Cancer Center from January 2005 to May 2013. Patients: The study included patients with metastatic DTC who received salvage therapy after their initial sorafenib failure (group 2). Patients who received first-line sorafenib only (group 1) were evaluated for comparison of overall survival (OS). Outcome Measures: Progression-free survival, best response, and median OS were measured. Results: Sixty-four patients with metastatic, radioactive iodine refractory DTC were included; 35 were in group 1 and 25 were in group 2, and the groups were well balanced. Median OS of all 64 patients receiving first line sorafenib was 37 months; median OS was significantly longer with salvage therapy compared with sorafenib alone (58 vs 28 months, P = .013). In group 2, 17 patients were evaluable for best response, although two patients had toxicity with sorafenib, which was discontinued before restaging. Best responses with first-line sorafenib were partial response in 2 of 15 (13%), stable disease in 10 of 15 (67%), and progressive disease in 3 of 15 (20%) patients. With salvage therapy, partial responses were seen in 7 of 17 (41%) and stable disease in 10 of 17 (59%) patients. Median progression-free survival was 7.4 months with first-line sorafenib and 11.4 months with salvage therapy. Salvage therapy included sunitinib (n = 4), pazopanib (n = 3), cabozantinib (n = 4), lenvatinib (n = 3), and vemurafenib (n = 3). Conclusions: Other targeted agents are effective salvage treatments after sorafenib failure, despite similar mechanisms of action, and should be offered to patients who are able to receive salvage therapy.
copUnited States
pubEndocrine Society
pmid24628550
doi10.1210/jc.2013-3588
oafree_for_read